Amaryl and Reyataz drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Amaryl (glimepiride) and Reyataz (atazanavir sulfate). Common drug interactions include abdominal pain among females and blood bilirubin increased among males.

The phase IV clinical study analyzes what interactions people have when they take Amaryl and Reyataz. It is created by eHealthMe based on reports of 21 people who take the same drugs from the FDA, and is updated regularly.

What is Amaryl?

Amaryl has active ingredients of glimepiride. It is often used in diabetes. eHealthMe is studying from 32,259 Amaryl users. Check the latest studies of Amaryl.

What is Reyataz?

Reyataz has active ingredients of atazanavir sulfate. It is often used in hiv infection. eHealthMe is studying from 11,386 Reyataz users. Check the latest studies of Reyataz.

On Jul, 16, 2026

21 people who take Amaryl and Reyataz together, and have interactions are studied.

What are the common drug interactions of Amaryl and Reyataz, by gender? *:

female:

Abdominal pain
Ascites (accumulation of fluid in the abdominal cavity)
Cholecystitis (infection of gallbladder)
Constipation
Dehydration (dryness resulting from the removal of water)
Diarrhoea
Dysphonia (speech disorder attributable to a disorder of phonation)
Endocarditis (inflammation in heart muscle)
Gastrointestinal disorder (functional problems of gastrointestinal tract)
Hepatic encephalopathy (spectrum of neuropsychiatric abnormalities in patients with liver failure)

male:

Blood bilirubin increased
Cholelithiasis (the presence or formation of gallstones in the gallbladder or bile ducts)
Perirectal abscess
Rectal cancer (cancer of rectum)
Pus in stool
Rash
C-reactive protein increased
Intraventricular haemorrhage (intraventricular bleeding)
Premature delivery
Lipoatrophy (localized loss of fat tissue)

What are the common drug interactions of Amaryl and Reyataz, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Cholelithiasis (the presence or formation of gallstones in the gallbladder or bile ducts)
Lipoatrophy (localized loss of fat tissue)
Melaena (the passage of black, tarry stools)
Platelet count decreased
Varices oesophageal (enlarged and swollen veins at the bottom of the oesophagus, near the stomach)
White blood cell count decreased
Abdominal pain
Ascites (accumulation of fluid in the abdominal cavity)
Cholecystitis (infection of gallbladder)
Constipation

40-49:

n/a

50-59:

Anaemia (lack of blood)
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body)
Diarrhoea
Perirectal abscess
Pus in stool
Rectal cancer (cancer of rectum)

60+:

C-reactive protein increased
Intraventricular haemorrhage (intraventricular bleeding)
Premature delivery

What are the existing conditions these people have? *

Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 12 people, 57.14%
Hepatitis C: 11 people, 52.38%
Urinary Tract Infection: 5 people, 23.81%
Perirectal Abscess: 5 people, 23.81%
Cancer Pain: 5 people, 23.81%
Acquired Immunodeficiency Syndrome (disease of the human immune system caused by the human immunodeficiency virus (hiv)): 5 people, 23.81%
Gastric Ulcer (stomach ulcer): 3 people, 14.29%
Insomnia (sleeplessness): 2 people, 9.52%

* Approximation only. Some reports may have incomplete information.

Do you take Amaryl and Reyataz?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously